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219 Abstract 
20 The aim of this study was to assess if the coupled analysis of the urinary protein to creatinine (UPC) 
21 ratio and of the GGT/UC ratio (the ratio between urinary -glutamyl transferase activity and urinary 
22 creatinine) may be used in treated leishmaniotic dogs to differentiate dogs with transient impairment 
23 of tubular function from dogs with persistent tubular damage. 
24 To this aim, 40 urine from 10 proteinuric and leishmaniotic dogs that at the first visit had high 
25 GGT/UC ratio, consistent with tubular proteinuriadamage, were collected and analyzed before 
26 treatments and 2, 4 and 6 weeks after treatment with N-methylglucamine antimoniate and allopurinol. 
27 Compared with pre-treatment values, at the end of the study period the UPC ratio decreased only in 
28 5/10 dogs, which, however, were still proteinuric or borderline proteinuric. Conversely, the GGT/CU 
29 ratio decreased in 8/10 dogs and in 3 of them the values at the end of the study period were below the 
30 threshold consistent with tubular proteinuria. The GGT/UC values at 6 weeks was significantly lower 
31 than before treatment. However, transient increases were frequent for both the analytes.
32 These results indicate that in most of the dogs that remain proteinuric after treatment, likely due to 
33 the persistent glomerular damage, the GGT/UC ratio tends to normalize. This suggests that in these 
34 dogs tubular proteinuria at admission depends on functional impairment of tubular cells likely due to 
35 the overflow of proteins from damaged glomeruli. However, tubular proteinuria occasionally persists, 
36 suggesting that tubulointerstitial damages persist even in dogs responsive to treatments. 
37
38 Keywords: Canine Leishmaniasis; Proteinuria; Chronic kidney disease; Renal biomarker
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341 Introduction
42 Canine leishmaniasis is characterized by a broad spectrum of symptomsclinical signs, due to a variety 
43 of lesions in different organs (Paltrinieri et al., 2016). Renal lesions may induce a life-threatening 
44 chronic renal disease (CKD) in affected dogs (Koutinas and Koutinas 2014). Leishmaniotic dogs may 
45 develop a proteinuric nephropathy that starts with an immune-mediated glomerulonephritis 
46 characterized by glomerular proteinuria that in turn induces functional or structural lesions in tubular 
47 cells. Therefore, mixed proteinuria is considered the most frequent finding in the advanced stages of 
48 canine leishmaniasis (Zatelli et al., 2003). Conversely, leishmanicidal treatments should decrease 
49 immuno-complex formation and deposition. This may modify the composition of urinary proteins 
50 over time. 
51 The presence and magnitude of proteinuria is considered a risk factor for the progression of renal 
52 disease (Jacob et al., 2005) and both the guidelines released by the American College of Veterinary 
53 Internal Medicine (Lees et al., 2005) and by the International Renal Interest Society (IRIS Canine GN 
54 Study Group, Diagnosis Subgroup, 2013), recommend to monitor proteinuria in dogs at risk for 
55 development of glomerular disease and to set up pharmacological treatments as soon as the dog 
56 became proteinuric. Moreover, the localization of proteinuria (glomerular vs tubular or both) should 
57 be a mandatory step in the investigation of canine proteinuria (Lees et al., 2005). Renal biopsy is the 
58 only reliable tool for localizing the renal lesions (Lees et al., 2005). However, the invasiveness of the 
59 technique limits its use in the clinical practice, especially when analyses should be repeated over time. 
60 Therefore, renal biopsy is recommended only in dogs not responding to treatments or in case of a 
61 rapid progression of kidney disease (IRIS Canine GN Study Group Diagnosis Subgroup, 2013). 
62 Sodium dodecyl-sulphate polyacrilamide gel electrophoresis (SDS-PAGE) or SDS agarose gel 
63 electrophoresis (SDS-AGE) differentiate the origin of proteinuria based on the molecular weight 
64 (MW) of urinary proteins (Schultze and Jensen 1998). The SDS techniques correlate with the results 
65 of renal biopsy, but their specificity is low (Brown et al., 2010; Zini et al., 2004). Moreover, although 
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466 less invasive than renal biopsy, these techniques are not available in routine practices that use in-
67 house analyzers. Recently, the measurement of urinary GGT, with the same analytical principle used 
68 on most in-house analyzers, has been proposed as a tool to detect tubular proteinuria in leishmaniotic 
69 dogs (Palacio et al., 1997), on which it may predict the results of SDS-AGE (Ibba et al., 2016). The 
70 enzyme -glutamyl transferase (GGT) is expressed in renal tubular cells (Braun et al., 1983). After 
71 detachment of the enzyme from the damaged tubular cells, GGT may be found in urine, where its 
72 activity is not influenced by serum levels of GGT since it does not undergo glomerular filtration and 
73 GGT activity may be measured using the same analytical principle used in many in-clinic analyzers. 
74 Therefore, increases in the ratio between urinary GGT and urinary creatinine (GGT/UC ratio) may 
75 early detect renal tubular dysfunction or damage (Brunker et al., 2009; Uechi et al., 1994) pending 
76 that GGT activity is measured just after sampling, to avoid storage artifacts (Flandrois et al., 1989). 
77 Based on what reported above, monitoring the magnitude of proteinuria is a milestone of the 
78 clinicopathological follow-up in the leishmaniotic patient either at first diagnosis or after treatment 
79 (Roura et al., 2013). Changes of protein to creatinine (UPC) ratio in dogs receiving N-
80 methylglucamine antimoniate and allopurinol or allopurinol alone have been already investigated 
81 (Pardo-Marin et al., 2017; Pierantozzi et al., 2013; Plevraki et al., 2006). Conversely, to our 
82 knowledge, only one study investigated separately the possible changes of urinary markers of 
83 glomerular or tubular injury during treatment (Pardo-Marin et al., 2017). However, this latter study 
84 was focused on a short post-treatment follow up, and provided contrasting results regarding 
85 biomarkers of tubular damage. A more reliable information would be useful in patient’s management 
86 since the identification of a persistent tubular damage may indicate the progression of canine 
87 leishmaniasis while a regression of tubular proteinuria may differentiate dogs with irreversible 
88 structural tubular changes from those that before treatment had a functional proteinuria due to the 
89 saturation of tubular cells subsequent to the overflow of glomerular proteins.
90 Hence, the aims of this study were to assess whether the simultaneous analysis of UPC and GGT/UC 
91 ratio might provide additional information compared with the traditional approach based on the 
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592 evaluation of the UPC ratio alone in leishmaniotic dogs that had tubular proteinuria at admission and 
93 successfully responded to treatments with N-methylglucamine antimoniate and allopurinol.
94
95 Material and methods
96
97 Animals and study design
98 This study was performed on 40 urine samples from 10 leishmaniotic dogs aged 2 to 11 years 
99 (median: 6 years), randomly selected among those referred to our institution for diagnosing, treating 
100 and monitoring leishmaniasis and that at the time of first diagnosis were in IRIS stage I (creatinine 
101 <1.5 mg/dL). The dogs  that were proteinuric (n=9) or borderline proteinuric (n=1) and had a 
102 GGT/CU higher than 0.81, i.e. the threshold consistent with a tubular component of proteinuria (Ibba 
103 et al., 2016). The study group included 6 crossbreed dogs, 1 Pitbull, 1 German shepherd, 1 Epagneul 
104 Breton, 1 English Setter. Eight Seven dogs were males, 3 were females. The age range was 2-11 years 
105 (median: 6 years). 
106 According to the current guidelines for diagnosis and classification of canine leishmaniasis 
107 (Paltrinieri et al., 2010), the diagnosis was based on the presence of typical symptoms clinical signs 
108 (e.g. cutaneous lesions, enlarged lymph nodes) and/or laboratory abnormalities (anemia, 
109 hyperproteinemia with inverted albumin:globulin ratio and polyclonal gammopathy) and on the 
110 detection of amastigotes in cytological specimens from lymph nodes with reactive 
111 (pyogranulomatous) lymphoadenopathy. Therefore, serology was not performed in all cases, since, 
112 based on the guidelines mentioned above, the detection of intralesional parasites is sufficient to 
113 classify the dogs as sick.
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6114 Dogs were treated with N-methylglucamine antimoniate (Glucantime, Merial Italia S.p.A., Milan, 
115 Italy; 100 mg/kg, SC once a day for 30 days) and allopurinol (Zyloric, Teofarma S.r.l. Pavia, Italy; 
116 10 mg/kg, orally twice a day for 6 months), as recommended by the current guidelines for treatment 
117 of canine leishmaniasis (Oliva et al., 2010).
118 Urine samples were collected, under informed consent by the owners, by cystocenthesis at the time 
119 of first diagnosis, before drugs administration, and after 2, 4 and 6 weeks after the beginning of the 
120 leishmanicidal treatment. According to the regulations of our Institution, when an informed consent 
121 is obtained from the owner, a formal approval from the Ethical Committee is not required if samples 
122 are performed for diagnostic or monitoring purposes, as in this case (EC decision 29 Oct 2012, 
123 renewed with the protocol n° 02-2016).
124
125 Unrinalysis and biochemical tests
126 Five millilitres of each sample have been centrifuged at 500 g for 5 mins. Then, 4.5 mLs of each 
127 supernatant were removed and aliquoted in other tubes. 
128 The remaining 0.5 mLs of each supernatant were used to resuspend the sediment and 50 μLs of the 
129 resuspended sediment were examined microscopically at 400× magnification (numerical aperture of 
130 the microscope lens  = 22), to count the mean number of red blood cells (RBCs) and white blood cells 
131 (WBCs) per high power field (hpf) and to exclude that samples had an active sediment (i.e. a sediment 
132 characterized by bacteriuria, presence of casts, or with more than 5 RBCs, WBCs, or epithelial 
133 cells/hpf).
134 One aliquot of the supernatant was used to measure GGT activity with the method proposed by Szasz 
135 (1969) in an automated spectrophotmeter (Mindray BC-120, Shenzen Mindray Biomedical, Shenzen, 
136 China) and to determine the urinary specific gravity (USG) using a manual refractometer (HR-160, 
137 Optika SRL, Ponteranica, Bergamo, Italy) whose accuracy was determined in house by comparing 
138 the results with those of a refractometer used in a previous study (Rossi et al., 2012). The other 
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7139 aliquots were frozen (-20°C) to determine the concentration of urinary proteins (UP) and urinary 
140 creatinine (UC) within one month from sampling.
141 Specifically, UPs were measured after thawing with an automated spectrophotometer (Cobas Mira, 
142 Roche Diagnostics, Basel, Switzerland) using pyrogallol red (Total Proteins High Sensitivity, Ben 
143 Biochemical Enterprise, Milan, Italy): samples with UPs >250 mg/dL were manually diluted 1:5 with 
144 distilled water and re-analysed to avoid inaccurate measurement for values outside the linearity of the 
145 method. The UC was measured with a modified Jaffe method (Real Time Diagnostic Systems, 
146 Viterbo, Italy). Samples were manually diluted 1:20 with distilled water to fit the linearity of the 
147 method (Rossi et al., 2012). 
148 The UPC ratio and the GGT/UC ratio were then calculated
149
150 Statistical analysis
151 Results regarding the the GGT/UC ratio recorded in sequential samplings were compared to each 
152 other using a non parametric ANOVA for paired data (Friedmann test), followed by a Bonferroni test 
153 to compare the results recorded after treatment with the baseline values (i.e. the values recorded at 
154 admission, before any treatment). Statistical analyses were run in a specific software (Analyse-it 
155 version 2.21, Analyse-it Software Ltd, Leeds, UK) and the level of significance was set at Pp<0.05
156
157 Results
158 All the dogs enrolled in the study remained in IRIS stage I during the study period and their clinical 
159 condition improved in 1-3 weeks of treatment.
160 Results regarding urinary findings are reported in table 1. 
161 Compared with values recorded at admission, at the end of the study period the UPC ratio decreased 
162 in 5/10 dogs, and increased in 5/10 dogs despite the amelioration of clinical signs. In 3 out of these 
163 latter 5 dogs the increase was severe (the UPC values increased more than 2 times). Three out of the 
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8164 nine proteinuric dogs became borderline proteinuric at the end of the study period while the borderline 
165 proteinuric dog became frankly proteinuric. Due to this variable behavior, no significant differences 
166 were found between the UPC values of sequential samplings (figure 1). 
167 Compared with the pre-treatment sample, at the end of the study period the GGT/CU ratio decreased 
168 in 8/10, remained substantially unchanged in 1/10 dogs and increased in 1/10 dogs. Moreover, in 3/10 
169 dogs values at the end of the study period the GGT/UC ratio decreased below the threshold consistent 
170 with tubular proteinuria (0.81) and in one out of these 3 dogs the decrease below this threshold 
171 occurred very early, at the second week of treatment. On a statistical point of view, values at 6 weeks 
172 were significantly lower than before treatment (figure 1). 
173 However, transient increases of both the UPC and the GGT/UC ratio were found also in those cases 
174 on which the value at the end of the study period finally decreased.
175
176 Discussion
177 The early phase of canine leishmaniasis is characterized by the progressive development of an 
178 immune-mediated glomerulopathy that induces a proteinuric nephropathy. The passage of proteins 
179 through the glomerular barrier may induce functional tubular impairment, that may theoretically be 
180 restored when the overflow of proteins decreases after anti-leishmaniotic treatment, or structural 
181 damages of tubular cells, that may persist despite the improvement of clinical signs after treatments. 
182 Hence, this study was designed to assess whether in leishmaniotic dogs with changes consistent with 
183 tubular proteinuria at first visit that showed an amelioration of clinical signs after conventional 
184 treatments, the simultaneous evaluation of the UPC ratio and the GGT/UC may provide additional 
185 information, compared with the recommended approach (Roura et al., 2013), that includes only the 
186 evaluation of the UPC. The addition of the GGT/UC may in fact differentiate dogs with transient 
187 impairment of tubular functions from those with permanent tubular damages. 
188 The GGT/UC has been chosen as an alternative method to investigate the presence of tubular damage 
189 since GGT may be released from the membranes of damaged tubular cells (Brunker et al., 2009) and 
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9190 its measurement in urine is less invasive then renal biopsy, that is the gold standard for assessing 
191 tubular damage (IRIS Canine GN Study Group, Diagnosis Subgroup, 2013), and is cheaper and easier 
192 to perform in house in routine practice than SDS electrophoretic techniques, that well correlate with 
193 results of renal biopsies (Brown et al., 2010; Zini et al., 2004) or than analytes that have been more 
194 recently proposed for the investigation of renal function such as retinol binding protein (RBP) or 
195 Neutrophil gelatinase-associated lipocalin (NGAL) (Hokamp et al., 2016) .
196 Since storage, either at 4°C or at -20°C, may inactivate the enzyme and provide false negative results 
197 (Flandrois et al., 1989), only samples on which the activity of GGT was measured soon after sampling 
198 and centrifugation were included in the study. 
199 The results of this study demonstrated that both the markers showed transiently increased during the 
200 study period, as already demonstrated in previous studies on proteinuria (Pierantozzi et al., 2013; 
201 Plevraki et al., 2006), likely depending on the release of antigens after the death of the parasite, with 
202 subsequent temporary worsening or immune-complex glomerulonephritis, that induces the increase 
203 of the UPC, and a subsequent overflow of proteins that it may be responsible for a transient functional 
204 impairment of tubular functions. 
205 Apart from these fluctuations, the UPC decreased, at the end of the study period, only in half of the 
206 dogs, on which, however, values remained in the proteinuric or borderline proteinuric range, and no 
207 significant differences compared with values recorded at admission were found. This is not surprising, 
208 since significant differences of the UPC may require up to 8 weeks after treatment (Pierantozzi et al.,, 
209 2013), and in most cases dogs were still proteinuric also in previous longitudinal studies (Pierantozzi 
210 et al., 2013; Plevraki et al., 2006), likely because the immune-mediated glomerulonephritis that 
211 characterizes canine leishmaniasis may induce permanent and non reversible glomerular damage 
212 (Koutinas and Koutinas, 2014)
213 Conversely, the GGT/UC decreased in the large majority of dogs, its decrease was statistically 
214 significant, and values decreased below the threshold consistent with tubular damage in 3 dogs, 
215 suggesting that in most cases the tubular proteins detectable at admission were likely due to a 
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10
216 functional impairment of tubular cells due to the overflow of proteins associated with glomerular 
217 damages and that this impairment disappear when the overflow of proteins decreases after treatment. 
218 This seems to contrast with a previous study on which no significant differences in the GGT/UC were 
219 found after 4 weeks of treatment compared with the pre-treatment levels (Pardo-Marin et al., 2017). 
220 However, in the cited study urinary GGT was measured in frozen urine and results may therefore 
221 have been biased by the storage artifacts mentioned above (Flandrois et al., 1989). This may explain 
222 why in the former study the GGT/UC did not decrease after treatment as the other tubular markers 
223 included in the study. Conversely, in the current study only in a minority of dogs the GGT/CU did 
224 not change at the end of the study period compared with pre-treatment values. This suggests that in a 
225 few dogs the tubulointerstitial damage persists after treatment, as evidenced in some studies based on 
226 histopathology (Aresu et al., 2013). 
227 This study has two main limitations: one is the low number of cases, that may reduce the statistical 
228 relevance of the results, due to the difficulties to obtain the whole series of samples during the follow 
229 up, in turn depending on a poor compliance of the owners. However, this allowed us to perform the 
230 study on a population with standardized inclusion criteria and time samplings. The second limitation 
231 is the lack of histopathologic findings, that cannot be repeatedly performed in field conditions for 
232 obvious ethical reasons, 
233 In conclusion, this study demonstrates that the coupled analysis of both the UPC and the GGT/UC 
234 ratio may provide additional information compared with the simple analysis of the UPC since this 
235 latter may remain in the proteinuric range due to the persistency of glomerular lesions, while the 
236 normalization of the GGT/UC may differentiate the dogs that at the first visit had a functional 
237 impairment of tubular cells, from those on which tubulointerstitial damages persist despite the 
238 normalization of clinical signs, on which the GGT/UC remain high. Despite the limitations mentioned 
239 above, these results are encouraging to design future studies, eventually based on longer observation 
240 times or on the comparison with the results of renal biopsies. Moreover, it would be interesting in the 
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241 future to assess whether the non invasive technique investigated in the current study may provide 
242 relevant clinical information on the management of dogs that do not respond to treatments.
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Figure captions
Figure 1: Data distribution and statistical analysis of results regarding the UPC ratio (A) and the 
GGT/UC ratio (B) recorded over time. The boxes indicate the I–III interquartile interval, the 
horizontal line corresponds to the median, vertical lines are the limits of outlier distribution according 
to the Tukey rule. Near outliers are indicated by the symbols “x” and far outliers with asterisks outside 
the boxes. The bolded asterisk within the boxes indicates a statistical difference (pP<0.05) compared 
with the baseline value
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1Table 1: Results recorded in the all the samples included in this study 
Before treatment 2 weeks 4 weeks 6 weeksDog n
UPC IRIS GGT UPC IRIS GGT UPC IRIS GGT UPC IRIS GGT
1 1.52 P 3.3 0.25 BP 1.42 0.27 BP 1.81 0.28 BP 0.94
2 1.04 P 1.04 0.79 P 0.89 2.30 P 2.54 1.36 P 1.17
3 1.45 P 2.48 1.31 P 2.99 1.23 P 7.01 0.76 P 3.18
4 1.57 P 3.94 0.81 P 4.97 0.35 BP 3.11 2.13 P 0.81
5 0.84 P 1.85 1.42 P 1.23 0.79 P 0.91 1.03 P 1.11
6 0.36 BP 0.85 0.63 P 0.75 1.74 P 1.01 2.10 P 0.69
7 2.36 P 0.91 1.18 P 0.49 0.05 NP 0.28 0.23 BP 0.15
8 1.89 P 0.81 1.47 P 0.77 1.40 P 0.52 1.21 P 0.61
9 3.11 P 2.15 0.34 BP 1.63 3.73 P 1.06 10.76 P 1.45
10 3.03 P 2.46 4.14 P 0.35 6.08 P 0.69 0.23 BP 0.09
BP = borderline proteinuric (UPC ratio between 0.2 and 0.5); GGT/CU = -glutamyl 
transferase/urinary creatinine ratio; IRIS = staging of proteinuria according to the International 
Renal Interest Society (IRIS); NP = non proteinuric (UPC ratio<0.2); P = proteinuric (UPC ratio 
>0.50); UPC = urinary protein to creatinine ratio
